Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against…
News
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with…
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed…
HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry
Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders The Head of the…
AmMax Bio Announces the Appointment of Biotechnology Executive, Michael Kavanaugh, M.D., as Independent Board Member
REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — AmMax Bio, Inc. (“AmMax”), a private…
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage…
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
Pivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrence…
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New…
Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
Pliant Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Oncotelic Presenting at BiotechGate Digital Partnering
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against…
Berkeley Lights Reports Fourth Quarter and Full Year 2021 Financial Results
Reports full year 2021 revenue of $85.4 million, above pre-announced preliminary range Reiterates 2022 revenue…
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 ROCHESTER,…
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients
JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in…
Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement
FORT LAUDERDALE, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022
SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company…
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical…
Alimera Sciences Reports Fourth Quarter and FY 2021 Results
Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of…